BMEA - NASDAQ

Biomea Fusion, Inc.

BMEA·NASDAQ

$1.38

+6.2%

HealthcareBiotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$82.10M

EPS-1.1800

P/E Ratio-1.17

Earnings Date08/03/2026

bmea

Capital Lease Obligations

Last Annual Value

1.59M

3-Year CAGR

-11%

5-Year CAGR

48%

10-Year CAGR

Adjust for Inflation

Biomea Fusion, Inc. Competitors Analysis of Capital Lease Obligations

BMEA · NASDAQ

Company	Capital Lease Obligations	CAGR 3Y	CAGR 5Y	CAGR 10Y
Biomea Fusion, Inc. NASDAQ:BMEA	1.59M	-46.4%	-11.0%	N/A
Fractyl Health, Inc. Common Stock NASDAQ:GUTS	25.96M	-3.1%	82.4%	N/A
Immunic, Inc. NASDAQ:IMUX	107.00K	-56.9%	-35.9%	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	0.00	N/A	N/A	N/A
Adicet Bio, Inc. NASDAQ:ACET	14.74M	-11.0%	-6.8%	N/A
aTyr Pharma, Inc. NASDAQ:ATYR	10.57M	-11.2%	50.3%	N/A
Pliant Therapeutics, Inc. NASDAQ:PLRX	29.11M	180.6%	32.3%	N/A
Surrozen, Inc. NASDAQ:SRZN	5.35M	16.5%	-7.3%	N/A
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL	35.70M	-6.1%	-4.3%	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	736.00K	-16.6%	-14.9%	N/A
Adverum Biotechnologies, Inc. NASDAQ:ADVM	91.70M	7.4%	-1.9%	N/A

Biomea Fusion, Inc. Fair Value Envelope

BMEA · NASDAQ

Our analysis suggests that BMEA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.38, this represents a potential HIDDEN relative to our calculated worth for Biomea Fusion, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.38

Related Guides

Blog Categories

Continue your BMEA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.